Goldman Sachs Group Inc vs TG Therapeutics Inc — how do they compare? Goldman Sachs Group Inc trades at $1,044.02 (market cap $302.01B), while TG Therapeutics Inc trades at $49.6 (market cap $7.58B). The key difference: Goldman Sachs Group Inc is far larger — about 39.8× TG Therapeutics Inc's market cap, and Goldman Sachs Group Inc pays a 1.93% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| GS | TGTX | |
|---|---|---|
Market Cap | $302.01B | $7.58B |
Volume | 2,592,735 | — |
Sector | Financials | Health |
52-Week High | $1.15K | $59.06 |
52-Week Low | $715.95 | $26.94 |
Dividend Yield | 1.93% | — |
Enterprise Value | — | $7.78B |
Signals from Pluang's Aura AI — not financial advice
Goldman Sachs (GS) trades at $1,034.41, showing minimal daily movement with a neutral technical stance. The company demonstrates strong fundamental performance with three consecutive quarterly earnings beats and robust profitability metrics including 31.68% net income margin and 18.34% ROE. Recent developments include securing lead roles in high-profile IPOs including Anthropic and SpaceX, positioning the firm for investment banking growth amid expectations of near-record M&A activity in 2026.
The outlook remains positive with analyst consensus targeting $1,160 representing 12% upside potential. Key opportunities include the upcoming IPO wave and strong investment banking pipeline, while risks involve volatile cash flow patterns and market sensitivity to economic conditions. The stock presents a compelling value proposition with a reasonable P/E of 15.97 amid strong earnings momentum.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Trailing returns across standard periods
Latest headlines on both assets
The Goldman Sachs Group, Inc., a bank holding company, is a global investment banking and securities firm specializing in investment banking, trading and principal investments, asset management and securities services. The Company provides services to corporations, financial institutions, governments, and high-net worth individuals.
Read more on GS →TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →